Shilpa Medicare Limited

NSEI:SHILPAMED Stok Raporu

Piyasa değeri: ₹77.5b

Shilpa Medicare Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Shilpa Medicare şirketinin kazançları yıllık ortalama -47.2% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 13.4% oranında artan oldu. Gelirler yıllık ortalama 6.5% oranında artan oldu. Shilpa Medicare şirketinin öz sermaye getirisi 2.6% olup, net marjı 5% dir.

Anahtar bilgiler

-47.2%

Kazanç büyüme oranı

-48.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi17.5%
Gelir büyüme oranı6.5%
Özkaynak getirisi2.6%
Net Marj5.0%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Sep 12
What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

Jul 05
Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Apr 12
What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Feb 21
Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

Jan 02
Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Jul 17
These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Mar 17
Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Sep 22
Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Sep 07
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Aug 14
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Jan 27
Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Sep 21
Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jun 17
Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

May 31
If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 07
Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Feb 20
Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jan 26
Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Gelir ve Gider Dağılımı

Shilpa Medicare nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NSEI:SHILPAMED Gelir, gider ve kazançlar (INR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 2412,1636113,0480
30 Jun 2411,8394482,8080
31 Mar 2411,5313193,0250
31 Dec 2311,248-72,9780
30 Sep 2311,008-1192,9730
30 Jun 2310,491-3212,8730
31 Mar 2310,517-3252,9690
31 Dec 2211,286513,0630
30 Sep 2211,3842133,0540
30 Jun 2211,6935992,7950
31 Mar 2211,4696072,8240
31 Dec 2110,1353952,6920
30 Sep 219,3243762,6120
30 Jun 219,1566312,4040
31 Mar 219,0161,4782,4730
31 Dec 209,1351,7392,2810
30 Sep 209,5912,2132,1680
30 Jun 209,6982,2672,0270
31 Mar 209,0821,5622,0430
31 Dec 198,8761,4552,0220
30 Sep 198,2411,0291,9830
30 Jun 196,9629441,8260
31 Mar 197,3371,1231,8340
31 Dec 187,6931,1931,7760
30 Sep 187,8141,2811,7040
30 Jun 188,2111,1671,5660
31 Mar 187,8941,0521,5550
31 Dec 177,7561,1331,4980
30 Sep 177,7311,1491,4220
30 Jun 177,7871,1901,3190
31 Mar 177,7951,0761,3300
31 Dec 167,5651,0481,1580
30 Sep 167,7351,1531,0920
30 Jun 167,3691,0241,0070
31 Mar 167,1661,0839340
31 Dec 156,8678861,170159
30 Sep 156,4307761,113159
30 Jun 156,2347288440
31 Mar 156,1387378550
31 Dec 146,14573199795
30 Sep 146,14379899195
30 Jun 145,9667877230
31 Mar 145,71475791395
31 Dec 135,02566476746

Kaliteli Kazançlar: SHILPAMED yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: SHILPAMED geçmişte karlı hale geldi.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SHILPAMED şirketinin kazançları son 5 yılda yılda 47.2% oranında azaldı.

Büyüme Hızlandırma: SHILPAMED son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.

Kazançlar vs. Sektör: SHILPAMED son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 20% ) karşılaştırılmasını zorlaştırıyor.


Özkaynak Getirisi

Yüksek ROE: SHILPAMED 'nin Özsermaye Getirisi ( 2.6% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin